01693nam 2200421 450 991070725550332120160614081836.0(CKB)5470000002462953(OCoLC)951671365(OCoLC)995470000002462953(EXLCZ)99547000000246295320160614d2013 ua 0engurmn|||||||||rdacontentrdamediardacarrierFDA lacks comprehensive data to determine whether risk evaluation and mitigation strategies improve drug safety[Washington, D.C.] :Department of Health and Human Services, Office of Inspector General,2013.1 online resource (34 pages) illustrationsTitle from title screen (viewed June 13, 2016)."February 2013.""OEI-04-11-00510."Includes bibliographical references.Food and Drug Administration lacks comprehensive data to determine whether risk evaluation and mitigation strategies improve drug safetyFDA lacks comprehensive data to determine whether REMS improve drug safetyMedicareDrugsRisk assessmentUnited StatesEvaluationDrugsUnited StatesSafety measuresEvaluationMedicare.DrugsRisk assessmentEvaluation.DrugsSafety measuresEvaluation.GPOGPOBOOK9910707255503321FDA lacks comprehensive data to determine whether risk evaluation and mitigation strategies improve drug safety3348157UNINA